Clinical Trial for a Outpatient Clinical Management for Complicated Acute Appendicitis
Launched by HJ23 · Sep 23, 2023
Trial Information
Current as of June 27, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how safe and effective it is to manage complicated acute appendicitis (a serious condition where the appendix becomes inflamed) on an outpatient basis, meaning patients can receive treatment without being admitted to the hospital. In this study, patients who have had surgery for acute appendicitis will be randomly placed into two groups: one group will stay in the hospital for care, while the other group will go home and be monitored from there. The goal is to see if treating patients at home is a good option for their recovery.
To participate in this trial, you need to be over 18 years old and have a certain level of health according to a classification system (the ASA classification) that rates how well you can handle anesthesia. You also need to live within 30 minutes of the hospital and have someone to help you at home. However, if you are pregnant, breastfeeding, or had surgery that took over 90 minutes, you won’t be able to join. The trial is not yet recruiting participants, but if you qualify, you would receive care and follow-up appointments to monitor your recovery, helping researchers learn more about outpatient management for this condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients over 18 years old
- • ASA classification (American Society of Anesthesiologists) less than or equal to 3
- • patients who live accompanied in a home at a maximum distance of 30 minutes from the hospital and an adequate cognitive capacity.
- Exclusion Criteria:
- • pregnancy or breastfeeding
- • complicated Acute Appendicitis
- • surgical management performed in more 90 minutes
About Hj23
hj23 is a dedicated clinical trial sponsor focused on advancing innovative therapeutic solutions across various medical fields. Committed to enhancing patient outcomes, hj23 specializes in the design, implementation, and management of clinical studies that adhere to the highest ethical and regulatory standards. With a team of experienced professionals, hj23 leverages cutting-edge research methodologies to support the development of new treatments, ensuring a rigorous approach to safety and efficacy. Our mission is to contribute to medical advancements while fostering collaboration with healthcare providers, regulatory bodies, and the patient community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Jordi Elvira Lopez, MD, PhD
Principal Investigator
HJ23
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported